Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
821
archived clinical trials in
Contraception

Study of the Contraceptive Efficacy and Safety of a NOMAC-E2 Combined Oral Contraceptive (COC)(P06448)
A Phase III, Randomized, Open-label, Active-controlled, Multicenter Trial to Study the Contraceptive Efficacy and Safety of the Commercial Batch of Oral Tablets of MK-8175A (Nomegestrol Acetate - 17ß-estradiol) in Healthy, Sexually-active Women Aged 18-50 Years
Status: Enrolling
Updated:  1/16/2013
Clinical Research Facility
mi
from
Spokane, WA
Study of the Contraceptive Efficacy and Safety of a NOMAC-E2 Combined Oral Contraceptive (COC)(P06448)
A Phase III, Randomized, Open-label, Active-controlled, Multicenter Trial to Study the Contraceptive Efficacy and Safety of the Commercial Batch of Oral Tablets of MK-8175A (Nomegestrol Acetate - 17ß-estradiol) in Healthy, Sexually-active Women Aged 18-50 Years
Status: Enrolling
Updated: 1/16/2013
Clinical Research Facility
mi
from
Spokane, WA
Click here to add this to my saved trials
The Effect of Nitroglycerin on the Intrauterine Device (IUD) Insertion Experience in Nulliparous Women
The Effect of Nitroglycerin on the IUD Insertion Experience in Nulliparous Women: a Pilot Study
Status: Enrolling
Updated:  2/4/2013
Planned Parenthood of the Columbia Willamette
mi
from
Portland, OR
The Effect of Nitroglycerin on the Intrauterine Device (IUD) Insertion Experience in Nulliparous Women
The Effect of Nitroglycerin on the IUD Insertion Experience in Nulliparous Women: a Pilot Study
Status: Enrolling
Updated: 2/4/2013
Planned Parenthood of the Columbia Willamette
mi
from
Portland, OR
Click here to add this to my saved trials
The Effect of Nitroglycerin on the Intrauterine Device (IUD) Insertion Experience in Nulliparous Women
The Effect of Nitroglycerin on the IUD Insertion Experience in Nulliparous Women: a Pilot Study
Status: Enrolling
Updated:  2/4/2013
Oregon Health and Science University
mi
from
Portland, OR
The Effect of Nitroglycerin on the Intrauterine Device (IUD) Insertion Experience in Nulliparous Women
The Effect of Nitroglycerin on the IUD Insertion Experience in Nulliparous Women: a Pilot Study
Status: Enrolling
Updated: 2/4/2013
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Postpartum Etonogestrel Implant for Adolescents
Etonogestrel-releasing Subdermal Implant for Adolescents in the Postpartum Period: a Randomized Controlled Trial
Status: Enrolling
Updated:  7/9/2013
University of North Carolina Hospitals
mi
from
Chapel Hill, NC
Postpartum Etonogestrel Implant for Adolescents
Etonogestrel-releasing Subdermal Implant for Adolescents in the Postpartum Period: a Randomized Controlled Trial
Status: Enrolling
Updated: 7/9/2013
University of North Carolina Hospitals
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Home or Office Visit for the Insertion of Implantable Birth Control
Home or Office Visit for Insertion of Etonogestrel Implant: A Pilot Study
Status: Enrolling
Updated:  2/4/2014
University Hospitals
mi
from
Cleveland, OH
Home or Office Visit for the Insertion of Implantable Birth Control
Home or Office Visit for Insertion of Etonogestrel Implant: A Pilot Study
Status: Enrolling
Updated: 2/4/2014
University Hospitals
mi
from
Cleveland, OH
Click here to add this to my saved trials
Medication Safety and Contraceptive Counseling for Reproductive Aged Women With Psychiatric Conditions
Medication Safety and Contraceptive Counseling for Reproductive Aged Women With Psychiatric Conditions
Status: Enrolling
Updated:  11/14/2014
Gifford Clinic at UCSD Outpatient Psychiatry
mi
from
San Diego, CA
Medication Safety and Contraceptive Counseling for Reproductive Aged Women With Psychiatric Conditions
Medication Safety and Contraceptive Counseling for Reproductive Aged Women With Psychiatric Conditions
Status: Enrolling
Updated: 11/14/2014
Gifford Clinic at UCSD Outpatient Psychiatry
mi
from
San Diego, CA
Click here to add this to my saved trials
EMR Referrals for Teratogen and Contraceptive Counseling for Category D or X Medication Users: RCT
Utilizing Electronic Medical Record Referrals for Teratogen and Contraceptive Counseling for Women Taking Category D or X Medications: A Randomized Controlled Trial
Status: Enrolling
Updated:  11/20/2014
CTIS Pregnancy Health Information Line at the University of California San Diego
mi
from
San Diego, CA
EMR Referrals for Teratogen and Contraceptive Counseling for Category D or X Medication Users: RCT
Utilizing Electronic Medical Record Referrals for Teratogen and Contraceptive Counseling for Women Taking Category D or X Medications: A Randomized Controlled Trial
Status: Enrolling
Updated: 11/20/2014
CTIS Pregnancy Health Information Line at the University of California San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
Nitrous Oxide for Pain Management During In-office Transcervical Sterilization
Nitrous Oxide for Pain Management During In-office Transcervical Sterilization
Status: Enrolling
Updated:  12/8/2014
UNM Center for Reproductive Health
mi
from
Albuquerque, NM
Nitrous Oxide for Pain Management During In-office Transcervical Sterilization
Nitrous Oxide for Pain Management During In-office Transcervical Sterilization
Status: Enrolling
Updated: 12/8/2014
UNM Center for Reproductive Health
mi
from
Albuquerque, NM
Click here to add this to my saved trials
LNG-IUS at 2 Weeks Postpartum
Intrauterine Contraceptive Insertion at Two-weeks Postpartum: A Study of Acceptability and Short-term Outcomes
Status: Enrolling
Updated:  4/6/2015
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
LNG-IUS at 2 Weeks Postpartum
Intrauterine Contraceptive Insertion at Two-weeks Postpartum: A Study of Acceptability and Short-term Outcomes
Status: Enrolling
Updated: 4/6/2015
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Cilostazol and Its Effects on Resumption of Meiosis in the Human Ovary
Cilostazol and Its Effects on Human Oocyte Maturation in Vivo: A Pilot Study
Status: Enrolling
Updated:  5/8/2015
University of Southern California Fertility Clinic
mi
from
Los Angeles, CA
Cilostazol and Its Effects on Resumption of Meiosis in the Human Ovary
Cilostazol and Its Effects on Human Oocyte Maturation in Vivo: A Pilot Study
Status: Enrolling
Updated: 5/8/2015
University of Southern California Fertility Clinic
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Effects of St. John's Wort on the Oral Contraceptive Hormone Levonorgestrel
Effects of St. John's Wort on Levonorgestrel
Status: Enrolling
Updated:  7/15/2015
University of Utah
mi
from
Salt Lake City, UT
Effects of St. John's Wort on the Oral Contraceptive Hormone Levonorgestrel
Effects of St. John's Wort on Levonorgestrel
Status: Enrolling
Updated: 7/15/2015
University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
US Cycle Control and Blood Pressure Study
Multi-Center, Double-Blind, Double-Dummy, Randomized, Parallel-Group Study to Evaluate Cycle Control, Bleeding Pattern, Blood Pressure, Lipid and Carbohydrate Metabolism of the Transdermal Contraceptive Patch (Material no. 80876395 / 2.1 mg Gestodene and 0.55 mg Ethinylestradiol) Versus an Oral Comparator Containing 20 µg Ethinylestradiol and 100 µg Levonorgestrel in a 21-day Regimen for 7 Cycles in 400 Women
Status: Enrolling
Updated:  9/23/2015
Clinical Research Facility
mi
from
Chandler, AZ
US Cycle Control and Blood Pressure Study
Multi-Center, Double-Blind, Double-Dummy, Randomized, Parallel-Group Study to Evaluate Cycle Control, Bleeding Pattern, Blood Pressure, Lipid and Carbohydrate Metabolism of the Transdermal Contraceptive Patch (Material no. 80876395 / 2.1 mg Gestodene and 0.55 mg Ethinylestradiol) Versus an Oral Comparator Containing 20 µg Ethinylestradiol and 100 µg Levonorgestrel in a 21-day Regimen for 7 Cycles in 400 Women
Status: Enrolling
Updated: 9/23/2015
Clinical Research Facility
mi
from
Chandler, AZ
Click here to add this to my saved trials
US Cycle Control and Blood Pressure Study
Multi-Center, Double-Blind, Double-Dummy, Randomized, Parallel-Group Study to Evaluate Cycle Control, Bleeding Pattern, Blood Pressure, Lipid and Carbohydrate Metabolism of the Transdermal Contraceptive Patch (Material no. 80876395 / 2.1 mg Gestodene and 0.55 mg Ethinylestradiol) Versus an Oral Comparator Containing 20 µg Ethinylestradiol and 100 µg Levonorgestrel in a 21-day Regimen for 7 Cycles in 400 Women
Status: Enrolling
Updated:  9/23/2015
Clinical Research Facility
mi
from
Glendale, AZ
US Cycle Control and Blood Pressure Study
Multi-Center, Double-Blind, Double-Dummy, Randomized, Parallel-Group Study to Evaluate Cycle Control, Bleeding Pattern, Blood Pressure, Lipid and Carbohydrate Metabolism of the Transdermal Contraceptive Patch (Material no. 80876395 / 2.1 mg Gestodene and 0.55 mg Ethinylestradiol) Versus an Oral Comparator Containing 20 µg Ethinylestradiol and 100 µg Levonorgestrel in a 21-day Regimen for 7 Cycles in 400 Women
Status: Enrolling
Updated: 9/23/2015
Clinical Research Facility
mi
from
Glendale, AZ
Click here to add this to my saved trials
US Cycle Control and Blood Pressure Study
Multi-Center, Double-Blind, Double-Dummy, Randomized, Parallel-Group Study to Evaluate Cycle Control, Bleeding Pattern, Blood Pressure, Lipid and Carbohydrate Metabolism of the Transdermal Contraceptive Patch (Material no. 80876395 / 2.1 mg Gestodene and 0.55 mg Ethinylestradiol) Versus an Oral Comparator Containing 20 µg Ethinylestradiol and 100 µg Levonorgestrel in a 21-day Regimen for 7 Cycles in 400 Women
Status: Enrolling
Updated:  9/23/2015
Clinical Research Facility
mi
from
Phoenix, AZ
US Cycle Control and Blood Pressure Study
Multi-Center, Double-Blind, Double-Dummy, Randomized, Parallel-Group Study to Evaluate Cycle Control, Bleeding Pattern, Blood Pressure, Lipid and Carbohydrate Metabolism of the Transdermal Contraceptive Patch (Material no. 80876395 / 2.1 mg Gestodene and 0.55 mg Ethinylestradiol) Versus an Oral Comparator Containing 20 µg Ethinylestradiol and 100 µg Levonorgestrel in a 21-day Regimen for 7 Cycles in 400 Women
Status: Enrolling
Updated: 9/23/2015
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
US Cycle Control and Blood Pressure Study
Multi-Center, Double-Blind, Double-Dummy, Randomized, Parallel-Group Study to Evaluate Cycle Control, Bleeding Pattern, Blood Pressure, Lipid and Carbohydrate Metabolism of the Transdermal Contraceptive Patch (Material no. 80876395 / 2.1 mg Gestodene and 0.55 mg Ethinylestradiol) Versus an Oral Comparator Containing 20 µg Ethinylestradiol and 100 µg Levonorgestrel in a 21-day Regimen for 7 Cycles in 400 Women
Status: Enrolling
Updated:  9/23/2015
Clinical Research Facility
mi
from
Tucson, AZ
US Cycle Control and Blood Pressure Study
Multi-Center, Double-Blind, Double-Dummy, Randomized, Parallel-Group Study to Evaluate Cycle Control, Bleeding Pattern, Blood Pressure, Lipid and Carbohydrate Metabolism of the Transdermal Contraceptive Patch (Material no. 80876395 / 2.1 mg Gestodene and 0.55 mg Ethinylestradiol) Versus an Oral Comparator Containing 20 µg Ethinylestradiol and 100 µg Levonorgestrel in a 21-day Regimen for 7 Cycles in 400 Women
Status: Enrolling
Updated: 9/23/2015
Clinical Research Facility
mi
from
Tucson, AZ
Click here to add this to my saved trials
US Cycle Control and Blood Pressure Study
Multi-Center, Double-Blind, Double-Dummy, Randomized, Parallel-Group Study to Evaluate Cycle Control, Bleeding Pattern, Blood Pressure, Lipid and Carbohydrate Metabolism of the Transdermal Contraceptive Patch (Material no. 80876395 / 2.1 mg Gestodene and 0.55 mg Ethinylestradiol) Versus an Oral Comparator Containing 20 µg Ethinylestradiol and 100 µg Levonorgestrel in a 21-day Regimen for 7 Cycles in 400 Women
Status: Enrolling
Updated:  9/23/2015
Clinical Research Facility
mi
from
Anaheim, CA
US Cycle Control and Blood Pressure Study
Multi-Center, Double-Blind, Double-Dummy, Randomized, Parallel-Group Study to Evaluate Cycle Control, Bleeding Pattern, Blood Pressure, Lipid and Carbohydrate Metabolism of the Transdermal Contraceptive Patch (Material no. 80876395 / 2.1 mg Gestodene and 0.55 mg Ethinylestradiol) Versus an Oral Comparator Containing 20 µg Ethinylestradiol and 100 µg Levonorgestrel in a 21-day Regimen for 7 Cycles in 400 Women
Status: Enrolling
Updated: 9/23/2015
Clinical Research Facility
mi
from
Anaheim, CA
Click here to add this to my saved trials
US Cycle Control and Blood Pressure Study
Multi-Center, Double-Blind, Double-Dummy, Randomized, Parallel-Group Study to Evaluate Cycle Control, Bleeding Pattern, Blood Pressure, Lipid and Carbohydrate Metabolism of the Transdermal Contraceptive Patch (Material no. 80876395 / 2.1 mg Gestodene and 0.55 mg Ethinylestradiol) Versus an Oral Comparator Containing 20 µg Ethinylestradiol and 100 µg Levonorgestrel in a 21-day Regimen for 7 Cycles in 400 Women
Status: Enrolling
Updated:  9/23/2015
Clinical Research Facility
mi
from
San Diego, CA
US Cycle Control and Blood Pressure Study
Multi-Center, Double-Blind, Double-Dummy, Randomized, Parallel-Group Study to Evaluate Cycle Control, Bleeding Pattern, Blood Pressure, Lipid and Carbohydrate Metabolism of the Transdermal Contraceptive Patch (Material no. 80876395 / 2.1 mg Gestodene and 0.55 mg Ethinylestradiol) Versus an Oral Comparator Containing 20 µg Ethinylestradiol and 100 µg Levonorgestrel in a 21-day Regimen for 7 Cycles in 400 Women
Status: Enrolling
Updated: 9/23/2015
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
US Cycle Control and Blood Pressure Study
Multi-Center, Double-Blind, Double-Dummy, Randomized, Parallel-Group Study to Evaluate Cycle Control, Bleeding Pattern, Blood Pressure, Lipid and Carbohydrate Metabolism of the Transdermal Contraceptive Patch (Material no. 80876395 / 2.1 mg Gestodene and 0.55 mg Ethinylestradiol) Versus an Oral Comparator Containing 20 µg Ethinylestradiol and 100 µg Levonorgestrel in a 21-day Regimen for 7 Cycles in 400 Women
Status: Enrolling
Updated:  9/23/2015
Clinical Research Facility
mi
from
Clearwater, FL
US Cycle Control and Blood Pressure Study
Multi-Center, Double-Blind, Double-Dummy, Randomized, Parallel-Group Study to Evaluate Cycle Control, Bleeding Pattern, Blood Pressure, Lipid and Carbohydrate Metabolism of the Transdermal Contraceptive Patch (Material no. 80876395 / 2.1 mg Gestodene and 0.55 mg Ethinylestradiol) Versus an Oral Comparator Containing 20 µg Ethinylestradiol and 100 µg Levonorgestrel in a 21-day Regimen for 7 Cycles in 400 Women
Status: Enrolling
Updated: 9/23/2015
Clinical Research Facility
mi
from
Clearwater, FL
Click here to add this to my saved trials
US Cycle Control and Blood Pressure Study
Multi-Center, Double-Blind, Double-Dummy, Randomized, Parallel-Group Study to Evaluate Cycle Control, Bleeding Pattern, Blood Pressure, Lipid and Carbohydrate Metabolism of the Transdermal Contraceptive Patch (Material no. 80876395 / 2.1 mg Gestodene and 0.55 mg Ethinylestradiol) Versus an Oral Comparator Containing 20 µg Ethinylestradiol and 100 µg Levonorgestrel in a 21-day Regimen for 7 Cycles in 400 Women
Status: Enrolling
Updated:  9/23/2015
Clinical Research Facility
mi
from
Daytona Beach, FL
US Cycle Control and Blood Pressure Study
Multi-Center, Double-Blind, Double-Dummy, Randomized, Parallel-Group Study to Evaluate Cycle Control, Bleeding Pattern, Blood Pressure, Lipid and Carbohydrate Metabolism of the Transdermal Contraceptive Patch (Material no. 80876395 / 2.1 mg Gestodene and 0.55 mg Ethinylestradiol) Versus an Oral Comparator Containing 20 µg Ethinylestradiol and 100 µg Levonorgestrel in a 21-day Regimen for 7 Cycles in 400 Women
Status: Enrolling
Updated: 9/23/2015
Clinical Research Facility
mi
from
Daytona Beach, FL
Click here to add this to my saved trials
US Cycle Control and Blood Pressure Study
Multi-Center, Double-Blind, Double-Dummy, Randomized, Parallel-Group Study to Evaluate Cycle Control, Bleeding Pattern, Blood Pressure, Lipid and Carbohydrate Metabolism of the Transdermal Contraceptive Patch (Material no. 80876395 / 2.1 mg Gestodene and 0.55 mg Ethinylestradiol) Versus an Oral Comparator Containing 20 µg Ethinylestradiol and 100 µg Levonorgestrel in a 21-day Regimen for 7 Cycles in 400 Women
Status: Enrolling
Updated:  9/23/2015
Clinical Research Facility
mi
from
Lake Worth, FL
US Cycle Control and Blood Pressure Study
Multi-Center, Double-Blind, Double-Dummy, Randomized, Parallel-Group Study to Evaluate Cycle Control, Bleeding Pattern, Blood Pressure, Lipid and Carbohydrate Metabolism of the Transdermal Contraceptive Patch (Material no. 80876395 / 2.1 mg Gestodene and 0.55 mg Ethinylestradiol) Versus an Oral Comparator Containing 20 µg Ethinylestradiol and 100 µg Levonorgestrel in a 21-day Regimen for 7 Cycles in 400 Women
Status: Enrolling
Updated: 9/23/2015
Clinical Research Facility
mi
from
Lake Worth, FL
Click here to add this to my saved trials
US Cycle Control and Blood Pressure Study
Multi-Center, Double-Blind, Double-Dummy, Randomized, Parallel-Group Study to Evaluate Cycle Control, Bleeding Pattern, Blood Pressure, Lipid and Carbohydrate Metabolism of the Transdermal Contraceptive Patch (Material no. 80876395 / 2.1 mg Gestodene and 0.55 mg Ethinylestradiol) Versus an Oral Comparator Containing 20 µg Ethinylestradiol and 100 µg Levonorgestrel in a 21-day Regimen for 7 Cycles in 400 Women
Status: Enrolling
Updated:  9/23/2015
Clinical Research Facility
mi
from
Leesburg, FL
US Cycle Control and Blood Pressure Study
Multi-Center, Double-Blind, Double-Dummy, Randomized, Parallel-Group Study to Evaluate Cycle Control, Bleeding Pattern, Blood Pressure, Lipid and Carbohydrate Metabolism of the Transdermal Contraceptive Patch (Material no. 80876395 / 2.1 mg Gestodene and 0.55 mg Ethinylestradiol) Versus an Oral Comparator Containing 20 µg Ethinylestradiol and 100 µg Levonorgestrel in a 21-day Regimen for 7 Cycles in 400 Women
Status: Enrolling
Updated: 9/23/2015
Clinical Research Facility
mi
from
Leesburg, FL
Click here to add this to my saved trials
US Cycle Control and Blood Pressure Study
Multi-Center, Double-Blind, Double-Dummy, Randomized, Parallel-Group Study to Evaluate Cycle Control, Bleeding Pattern, Blood Pressure, Lipid and Carbohydrate Metabolism of the Transdermal Contraceptive Patch (Material no. 80876395 / 2.1 mg Gestodene and 0.55 mg Ethinylestradiol) Versus an Oral Comparator Containing 20 µg Ethinylestradiol and 100 µg Levonorgestrel in a 21-day Regimen for 7 Cycles in 400 Women
Status: Enrolling
Updated:  9/23/2015
Clinical Research Facility
mi
from
Miami, FL
US Cycle Control and Blood Pressure Study
Multi-Center, Double-Blind, Double-Dummy, Randomized, Parallel-Group Study to Evaluate Cycle Control, Bleeding Pattern, Blood Pressure, Lipid and Carbohydrate Metabolism of the Transdermal Contraceptive Patch (Material no. 80876395 / 2.1 mg Gestodene and 0.55 mg Ethinylestradiol) Versus an Oral Comparator Containing 20 µg Ethinylestradiol and 100 µg Levonorgestrel in a 21-day Regimen for 7 Cycles in 400 Women
Status: Enrolling
Updated: 9/23/2015
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
US Cycle Control and Blood Pressure Study
Multi-Center, Double-Blind, Double-Dummy, Randomized, Parallel-Group Study to Evaluate Cycle Control, Bleeding Pattern, Blood Pressure, Lipid and Carbohydrate Metabolism of the Transdermal Contraceptive Patch (Material no. 80876395 / 2.1 mg Gestodene and 0.55 mg Ethinylestradiol) Versus an Oral Comparator Containing 20 µg Ethinylestradiol and 100 µg Levonorgestrel in a 21-day Regimen for 7 Cycles in 400 Women
Status: Enrolling
Updated:  9/23/2015
Clinical Research Facility
mi
from
Atlanta, GA
US Cycle Control and Blood Pressure Study
Multi-Center, Double-Blind, Double-Dummy, Randomized, Parallel-Group Study to Evaluate Cycle Control, Bleeding Pattern, Blood Pressure, Lipid and Carbohydrate Metabolism of the Transdermal Contraceptive Patch (Material no. 80876395 / 2.1 mg Gestodene and 0.55 mg Ethinylestradiol) Versus an Oral Comparator Containing 20 µg Ethinylestradiol and 100 µg Levonorgestrel in a 21-day Regimen for 7 Cycles in 400 Women
Status: Enrolling
Updated: 9/23/2015
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
US Cycle Control and Blood Pressure Study
Multi-Center, Double-Blind, Double-Dummy, Randomized, Parallel-Group Study to Evaluate Cycle Control, Bleeding Pattern, Blood Pressure, Lipid and Carbohydrate Metabolism of the Transdermal Contraceptive Patch (Material no. 80876395 / 2.1 mg Gestodene and 0.55 mg Ethinylestradiol) Versus an Oral Comparator Containing 20 µg Ethinylestradiol and 100 µg Levonorgestrel in a 21-day Regimen for 7 Cycles in 400 Women
Status: Enrolling
Updated:  9/23/2015
Clinical Research Facility
mi
from
Decatur, GA
US Cycle Control and Blood Pressure Study
Multi-Center, Double-Blind, Double-Dummy, Randomized, Parallel-Group Study to Evaluate Cycle Control, Bleeding Pattern, Blood Pressure, Lipid and Carbohydrate Metabolism of the Transdermal Contraceptive Patch (Material no. 80876395 / 2.1 mg Gestodene and 0.55 mg Ethinylestradiol) Versus an Oral Comparator Containing 20 µg Ethinylestradiol and 100 µg Levonorgestrel in a 21-day Regimen for 7 Cycles in 400 Women
Status: Enrolling
Updated: 9/23/2015
Clinical Research Facility
mi
from
Decatur, GA
Click here to add this to my saved trials
US Cycle Control and Blood Pressure Study
Multi-Center, Double-Blind, Double-Dummy, Randomized, Parallel-Group Study to Evaluate Cycle Control, Bleeding Pattern, Blood Pressure, Lipid and Carbohydrate Metabolism of the Transdermal Contraceptive Patch (Material no. 80876395 / 2.1 mg Gestodene and 0.55 mg Ethinylestradiol) Versus an Oral Comparator Containing 20 µg Ethinylestradiol and 100 µg Levonorgestrel in a 21-day Regimen for 7 Cycles in 400 Women
Status: Enrolling
Updated:  9/23/2015
Clinical Research Facility
mi
from
Metairie, LA
US Cycle Control and Blood Pressure Study
Multi-Center, Double-Blind, Double-Dummy, Randomized, Parallel-Group Study to Evaluate Cycle Control, Bleeding Pattern, Blood Pressure, Lipid and Carbohydrate Metabolism of the Transdermal Contraceptive Patch (Material no. 80876395 / 2.1 mg Gestodene and 0.55 mg Ethinylestradiol) Versus an Oral Comparator Containing 20 µg Ethinylestradiol and 100 µg Levonorgestrel in a 21-day Regimen for 7 Cycles in 400 Women
Status: Enrolling
Updated: 9/23/2015
Clinical Research Facility
mi
from
Metairie, LA
Click here to add this to my saved trials
US Cycle Control and Blood Pressure Study
Multi-Center, Double-Blind, Double-Dummy, Randomized, Parallel-Group Study to Evaluate Cycle Control, Bleeding Pattern, Blood Pressure, Lipid and Carbohydrate Metabolism of the Transdermal Contraceptive Patch (Material no. 80876395 / 2.1 mg Gestodene and 0.55 mg Ethinylestradiol) Versus an Oral Comparator Containing 20 µg Ethinylestradiol and 100 µg Levonorgestrel in a 21-day Regimen for 7 Cycles in 400 Women
Status: Enrolling
Updated:  9/23/2015
Clinical Research Facility
mi
from
Kalamazoo, MI
US Cycle Control and Blood Pressure Study
Multi-Center, Double-Blind, Double-Dummy, Randomized, Parallel-Group Study to Evaluate Cycle Control, Bleeding Pattern, Blood Pressure, Lipid and Carbohydrate Metabolism of the Transdermal Contraceptive Patch (Material no. 80876395 / 2.1 mg Gestodene and 0.55 mg Ethinylestradiol) Versus an Oral Comparator Containing 20 µg Ethinylestradiol and 100 µg Levonorgestrel in a 21-day Regimen for 7 Cycles in 400 Women
Status: Enrolling
Updated: 9/23/2015
Clinical Research Facility
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
US Cycle Control and Blood Pressure Study
Multi-Center, Double-Blind, Double-Dummy, Randomized, Parallel-Group Study to Evaluate Cycle Control, Bleeding Pattern, Blood Pressure, Lipid and Carbohydrate Metabolism of the Transdermal Contraceptive Patch (Material no. 80876395 / 2.1 mg Gestodene and 0.55 mg Ethinylestradiol) Versus an Oral Comparator Containing 20 µg Ethinylestradiol and 100 µg Levonorgestrel in a 21-day Regimen for 7 Cycles in 400 Women
Status: Enrolling
Updated:  9/23/2015
Clinical Research Facility
mi
from
St. Louis, MO
US Cycle Control and Blood Pressure Study
Multi-Center, Double-Blind, Double-Dummy, Randomized, Parallel-Group Study to Evaluate Cycle Control, Bleeding Pattern, Blood Pressure, Lipid and Carbohydrate Metabolism of the Transdermal Contraceptive Patch (Material no. 80876395 / 2.1 mg Gestodene and 0.55 mg Ethinylestradiol) Versus an Oral Comparator Containing 20 µg Ethinylestradiol and 100 µg Levonorgestrel in a 21-day Regimen for 7 Cycles in 400 Women
Status: Enrolling
Updated: 9/23/2015
Clinical Research Facility
mi
from
St. Louis, MO
Click here to add this to my saved trials
US Cycle Control and Blood Pressure Study
Multi-Center, Double-Blind, Double-Dummy, Randomized, Parallel-Group Study to Evaluate Cycle Control, Bleeding Pattern, Blood Pressure, Lipid and Carbohydrate Metabolism of the Transdermal Contraceptive Patch (Material no. 80876395 / 2.1 mg Gestodene and 0.55 mg Ethinylestradiol) Versus an Oral Comparator Containing 20 µg Ethinylestradiol and 100 µg Levonorgestrel in a 21-day Regimen for 7 Cycles in 400 Women
Status: Enrolling
Updated:  9/23/2015
Clinical Research Facility
mi
from
Las Vegas, NV
US Cycle Control and Blood Pressure Study
Multi-Center, Double-Blind, Double-Dummy, Randomized, Parallel-Group Study to Evaluate Cycle Control, Bleeding Pattern, Blood Pressure, Lipid and Carbohydrate Metabolism of the Transdermal Contraceptive Patch (Material no. 80876395 / 2.1 mg Gestodene and 0.55 mg Ethinylestradiol) Versus an Oral Comparator Containing 20 µg Ethinylestradiol and 100 µg Levonorgestrel in a 21-day Regimen for 7 Cycles in 400 Women
Status: Enrolling
Updated: 9/23/2015
Clinical Research Facility
mi
from
Las Vegas, NV
Click here to add this to my saved trials
US Cycle Control and Blood Pressure Study
Multi-Center, Double-Blind, Double-Dummy, Randomized, Parallel-Group Study to Evaluate Cycle Control, Bleeding Pattern, Blood Pressure, Lipid and Carbohydrate Metabolism of the Transdermal Contraceptive Patch (Material no. 80876395 / 2.1 mg Gestodene and 0.55 mg Ethinylestradiol) Versus an Oral Comparator Containing 20 µg Ethinylestradiol and 100 µg Levonorgestrel in a 21-day Regimen for 7 Cycles in 400 Women
Status: Enrolling
Updated:  9/23/2015
Clinical Research Facility
mi
from
New Brunswick, NJ
US Cycle Control and Blood Pressure Study
Multi-Center, Double-Blind, Double-Dummy, Randomized, Parallel-Group Study to Evaluate Cycle Control, Bleeding Pattern, Blood Pressure, Lipid and Carbohydrate Metabolism of the Transdermal Contraceptive Patch (Material no. 80876395 / 2.1 mg Gestodene and 0.55 mg Ethinylestradiol) Versus an Oral Comparator Containing 20 µg Ethinylestradiol and 100 µg Levonorgestrel in a 21-day Regimen for 7 Cycles in 400 Women
Status: Enrolling
Updated: 9/23/2015
Clinical Research Facility
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
US Cycle Control and Blood Pressure Study
Multi-Center, Double-Blind, Double-Dummy, Randomized, Parallel-Group Study to Evaluate Cycle Control, Bleeding Pattern, Blood Pressure, Lipid and Carbohydrate Metabolism of the Transdermal Contraceptive Patch (Material no. 80876395 / 2.1 mg Gestodene and 0.55 mg Ethinylestradiol) Versus an Oral Comparator Containing 20 µg Ethinylestradiol and 100 µg Levonorgestrel in a 21-day Regimen for 7 Cycles in 400 Women
Status: Enrolling
Updated:  9/23/2015
Clinical Research Facility
mi
from
Winston-Salem, NC
US Cycle Control and Blood Pressure Study
Multi-Center, Double-Blind, Double-Dummy, Randomized, Parallel-Group Study to Evaluate Cycle Control, Bleeding Pattern, Blood Pressure, Lipid and Carbohydrate Metabolism of the Transdermal Contraceptive Patch (Material no. 80876395 / 2.1 mg Gestodene and 0.55 mg Ethinylestradiol) Versus an Oral Comparator Containing 20 µg Ethinylestradiol and 100 µg Levonorgestrel in a 21-day Regimen for 7 Cycles in 400 Women
Status: Enrolling
Updated: 9/23/2015
Clinical Research Facility
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
US Cycle Control and Blood Pressure Study
Multi-Center, Double-Blind, Double-Dummy, Randomized, Parallel-Group Study to Evaluate Cycle Control, Bleeding Pattern, Blood Pressure, Lipid and Carbohydrate Metabolism of the Transdermal Contraceptive Patch (Material no. 80876395 / 2.1 mg Gestodene and 0.55 mg Ethinylestradiol) Versus an Oral Comparator Containing 20 µg Ethinylestradiol and 100 µg Levonorgestrel in a 21-day Regimen for 7 Cycles in 400 Women
Status: Enrolling
Updated:  9/23/2015
Clinical Research Facility
mi
from
Cincinnati, OH
US Cycle Control and Blood Pressure Study
Multi-Center, Double-Blind, Double-Dummy, Randomized, Parallel-Group Study to Evaluate Cycle Control, Bleeding Pattern, Blood Pressure, Lipid and Carbohydrate Metabolism of the Transdermal Contraceptive Patch (Material no. 80876395 / 2.1 mg Gestodene and 0.55 mg Ethinylestradiol) Versus an Oral Comparator Containing 20 µg Ethinylestradiol and 100 µg Levonorgestrel in a 21-day Regimen for 7 Cycles in 400 Women
Status: Enrolling
Updated: 9/23/2015
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
US Cycle Control and Blood Pressure Study
Multi-Center, Double-Blind, Double-Dummy, Randomized, Parallel-Group Study to Evaluate Cycle Control, Bleeding Pattern, Blood Pressure, Lipid and Carbohydrate Metabolism of the Transdermal Contraceptive Patch (Material no. 80876395 / 2.1 mg Gestodene and 0.55 mg Ethinylestradiol) Versus an Oral Comparator Containing 20 µg Ethinylestradiol and 100 µg Levonorgestrel in a 21-day Regimen for 7 Cycles in 400 Women
Status: Enrolling
Updated:  9/23/2015
Clinical Research Facility
mi
from
Philadelphia, PA
US Cycle Control and Blood Pressure Study
Multi-Center, Double-Blind, Double-Dummy, Randomized, Parallel-Group Study to Evaluate Cycle Control, Bleeding Pattern, Blood Pressure, Lipid and Carbohydrate Metabolism of the Transdermal Contraceptive Patch (Material no. 80876395 / 2.1 mg Gestodene and 0.55 mg Ethinylestradiol) Versus an Oral Comparator Containing 20 µg Ethinylestradiol and 100 µg Levonorgestrel in a 21-day Regimen for 7 Cycles in 400 Women
Status: Enrolling
Updated: 9/23/2015
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
US Cycle Control and Blood Pressure Study
Multi-Center, Double-Blind, Double-Dummy, Randomized, Parallel-Group Study to Evaluate Cycle Control, Bleeding Pattern, Blood Pressure, Lipid and Carbohydrate Metabolism of the Transdermal Contraceptive Patch (Material no. 80876395 / 2.1 mg Gestodene and 0.55 mg Ethinylestradiol) Versus an Oral Comparator Containing 20 µg Ethinylestradiol and 100 µg Levonorgestrel in a 21-day Regimen for 7 Cycles in 400 Women
Status: Enrolling
Updated:  9/23/2015
Clinical Research Facility
mi
from
Pittsburgh, PA
US Cycle Control and Blood Pressure Study
Multi-Center, Double-Blind, Double-Dummy, Randomized, Parallel-Group Study to Evaluate Cycle Control, Bleeding Pattern, Blood Pressure, Lipid and Carbohydrate Metabolism of the Transdermal Contraceptive Patch (Material no. 80876395 / 2.1 mg Gestodene and 0.55 mg Ethinylestradiol) Versus an Oral Comparator Containing 20 µg Ethinylestradiol and 100 µg Levonorgestrel in a 21-day Regimen for 7 Cycles in 400 Women
Status: Enrolling
Updated: 9/23/2015
Clinical Research Facility
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
US Cycle Control and Blood Pressure Study
Multi-Center, Double-Blind, Double-Dummy, Randomized, Parallel-Group Study to Evaluate Cycle Control, Bleeding Pattern, Blood Pressure, Lipid and Carbohydrate Metabolism of the Transdermal Contraceptive Patch (Material no. 80876395 / 2.1 mg Gestodene and 0.55 mg Ethinylestradiol) Versus an Oral Comparator Containing 20 µg Ethinylestradiol and 100 µg Levonorgestrel in a 21-day Regimen for 7 Cycles in 400 Women
Status: Enrolling
Updated:  9/23/2015
Clinical Research Facility
mi
from
Wexford, PA
US Cycle Control and Blood Pressure Study
Multi-Center, Double-Blind, Double-Dummy, Randomized, Parallel-Group Study to Evaluate Cycle Control, Bleeding Pattern, Blood Pressure, Lipid and Carbohydrate Metabolism of the Transdermal Contraceptive Patch (Material no. 80876395 / 2.1 mg Gestodene and 0.55 mg Ethinylestradiol) Versus an Oral Comparator Containing 20 µg Ethinylestradiol and 100 µg Levonorgestrel in a 21-day Regimen for 7 Cycles in 400 Women
Status: Enrolling
Updated: 9/23/2015
Clinical Research Facility
mi
from
Wexford, PA
Click here to add this to my saved trials
US Cycle Control and Blood Pressure Study
Multi-Center, Double-Blind, Double-Dummy, Randomized, Parallel-Group Study to Evaluate Cycle Control, Bleeding Pattern, Blood Pressure, Lipid and Carbohydrate Metabolism of the Transdermal Contraceptive Patch (Material no. 80876395 / 2.1 mg Gestodene and 0.55 mg Ethinylestradiol) Versus an Oral Comparator Containing 20 µg Ethinylestradiol and 100 µg Levonorgestrel in a 21-day Regimen for 7 Cycles in 400 Women
Status: Enrolling
Updated:  9/23/2015
Clinical Research Facility
mi
from
Columbia, SC
US Cycle Control and Blood Pressure Study
Multi-Center, Double-Blind, Double-Dummy, Randomized, Parallel-Group Study to Evaluate Cycle Control, Bleeding Pattern, Blood Pressure, Lipid and Carbohydrate Metabolism of the Transdermal Contraceptive Patch (Material no. 80876395 / 2.1 mg Gestodene and 0.55 mg Ethinylestradiol) Versus an Oral Comparator Containing 20 µg Ethinylestradiol and 100 µg Levonorgestrel in a 21-day Regimen for 7 Cycles in 400 Women
Status: Enrolling
Updated: 9/23/2015
Clinical Research Facility
mi
from
Columbia, SC
Click here to add this to my saved trials
US Cycle Control and Blood Pressure Study
Multi-Center, Double-Blind, Double-Dummy, Randomized, Parallel-Group Study to Evaluate Cycle Control, Bleeding Pattern, Blood Pressure, Lipid and Carbohydrate Metabolism of the Transdermal Contraceptive Patch (Material no. 80876395 / 2.1 mg Gestodene and 0.55 mg Ethinylestradiol) Versus an Oral Comparator Containing 20 µg Ethinylestradiol and 100 µg Levonorgestrel in a 21-day Regimen for 7 Cycles in 400 Women
Status: Enrolling
Updated:  9/23/2015
Clinical Research Facility
mi
from
Richmond, VA
US Cycle Control and Blood Pressure Study
Multi-Center, Double-Blind, Double-Dummy, Randomized, Parallel-Group Study to Evaluate Cycle Control, Bleeding Pattern, Blood Pressure, Lipid and Carbohydrate Metabolism of the Transdermal Contraceptive Patch (Material no. 80876395 / 2.1 mg Gestodene and 0.55 mg Ethinylestradiol) Versus an Oral Comparator Containing 20 µg Ethinylestradiol and 100 µg Levonorgestrel in a 21-day Regimen for 7 Cycles in 400 Women
Status: Enrolling
Updated: 9/23/2015
Clinical Research Facility
mi
from
Richmond, VA
Click here to add this to my saved trials
US Cycle Control and Blood Pressure Study
Multi-Center, Double-Blind, Double-Dummy, Randomized, Parallel-Group Study to Evaluate Cycle Control, Bleeding Pattern, Blood Pressure, Lipid and Carbohydrate Metabolism of the Transdermal Contraceptive Patch (Material no. 80876395 / 2.1 mg Gestodene and 0.55 mg Ethinylestradiol) Versus an Oral Comparator Containing 20 µg Ethinylestradiol and 100 µg Levonorgestrel in a 21-day Regimen for 7 Cycles in 400 Women
Status: Enrolling
Updated:  9/23/2015
Clinical Research Facility
mi
from
Renton, WA
US Cycle Control and Blood Pressure Study
Multi-Center, Double-Blind, Double-Dummy, Randomized, Parallel-Group Study to Evaluate Cycle Control, Bleeding Pattern, Blood Pressure, Lipid and Carbohydrate Metabolism of the Transdermal Contraceptive Patch (Material no. 80876395 / 2.1 mg Gestodene and 0.55 mg Ethinylestradiol) Versus an Oral Comparator Containing 20 µg Ethinylestradiol and 100 µg Levonorgestrel in a 21-day Regimen for 7 Cycles in 400 Women
Status: Enrolling
Updated: 9/23/2015
Clinical Research Facility
mi
from
Renton, WA
Click here to add this to my saved trials
US Cycle Control and Blood Pressure Study
Multi-Center, Double-Blind, Double-Dummy, Randomized, Parallel-Group Study to Evaluate Cycle Control, Bleeding Pattern, Blood Pressure, Lipid and Carbohydrate Metabolism of the Transdermal Contraceptive Patch (Material no. 80876395 / 2.1 mg Gestodene and 0.55 mg Ethinylestradiol) Versus an Oral Comparator Containing 20 µg Ethinylestradiol and 100 µg Levonorgestrel in a 21-day Regimen for 7 Cycles in 400 Women
Status: Enrolling
Updated:  9/23/2015
Clinical Research Facility
mi
from
Seattle, WA
US Cycle Control and Blood Pressure Study
Multi-Center, Double-Blind, Double-Dummy, Randomized, Parallel-Group Study to Evaluate Cycle Control, Bleeding Pattern, Blood Pressure, Lipid and Carbohydrate Metabolism of the Transdermal Contraceptive Patch (Material no. 80876395 / 2.1 mg Gestodene and 0.55 mg Ethinylestradiol) Versus an Oral Comparator Containing 20 µg Ethinylestradiol and 100 µg Levonorgestrel in a 21-day Regimen for 7 Cycles in 400 Women
Status: Enrolling
Updated: 9/23/2015
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
US Cycle Control and Blood Pressure Study
Multi-Center, Double-Blind, Double-Dummy, Randomized, Parallel-Group Study to Evaluate Cycle Control, Bleeding Pattern, Blood Pressure, Lipid and Carbohydrate Metabolism of the Transdermal Contraceptive Patch (Material no. 80876395 / 2.1 mg Gestodene and 0.55 mg Ethinylestradiol) Versus an Oral Comparator Containing 20 µg Ethinylestradiol and 100 µg Levonorgestrel in a 21-day Regimen for 7 Cycles in 400 Women
Status: Enrolling
Updated:  9/23/2015
Clinical Research Facility
mi
from
La Crosse, WI
US Cycle Control and Blood Pressure Study
Multi-Center, Double-Blind, Double-Dummy, Randomized, Parallel-Group Study to Evaluate Cycle Control, Bleeding Pattern, Blood Pressure, Lipid and Carbohydrate Metabolism of the Transdermal Contraceptive Patch (Material no. 80876395 / 2.1 mg Gestodene and 0.55 mg Ethinylestradiol) Versus an Oral Comparator Containing 20 µg Ethinylestradiol and 100 µg Levonorgestrel in a 21-day Regimen for 7 Cycles in 400 Women
Status: Enrolling
Updated: 9/23/2015
Clinical Research Facility
mi
from
La Crosse, WI
Click here to add this to my saved trials
Stage Matched Intervention to Increase Dual Method Use
Stage Matched Intervention to Increase Dual Method Use
Status: Enrolling
Updated:  10/6/2015
Women and Infants Hospital
mi
from
Providence, RI
Stage Matched Intervention to Increase Dual Method Use
Stage Matched Intervention to Increase Dual Method Use
Status: Enrolling
Updated: 10/6/2015
Women and Infants Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Comparison of the Levonorgestrel IUD and the Copper IUD Placed in the Immediate Postplacental Period: A Prospective Cohort Study
Comparison of the Levonorgestrel IUD and the Copper IUD Placed in the Immediate Postplacental Period: A Prospective Cohort Study
Status: Enrolling
Updated:  10/8/2015
University of Colorado Denver
mi
from
Aurora, CO
Comparison of the Levonorgestrel IUD and the Copper IUD Placed in the Immediate Postplacental Period: A Prospective Cohort Study
Comparison of the Levonorgestrel IUD and the Copper IUD Placed in the Immediate Postplacental Period: A Prospective Cohort Study
Status: Enrolling
Updated: 10/8/2015
University of Colorado Denver
mi
from
Aurora, CO
Click here to add this to my saved trials
ChoicesPlus: Reducing Alcohol- and Tobacco-Exposed Pregnancy
ChoicesPlus: Preconception Approach to Reducing Alcohol- and Tobacco-Exposed Pregnancy
Status: Enrolling
Updated:  11/23/2015
Settegast Health Center
mi
from
Houston, TX
ChoicesPlus: Reducing Alcohol- and Tobacco-Exposed Pregnancy
ChoicesPlus: Preconception Approach to Reducing Alcohol- and Tobacco-Exposed Pregnancy
Status: Enrolling
Updated: 11/23/2015
Settegast Health Center
mi
from
Houston, TX
Click here to add this to my saved trials
ChoicesPlus: Reducing Alcohol- and Tobacco-Exposed Pregnancy
ChoicesPlus: Preconception Approach to Reducing Alcohol- and Tobacco-Exposed Pregnancy
Status: Enrolling
Updated:  11/23/2015
Strawberry Health Center
mi
from
Pasadena, TX
ChoicesPlus: Reducing Alcohol- and Tobacco-Exposed Pregnancy
ChoicesPlus: Preconception Approach to Reducing Alcohol- and Tobacco-Exposed Pregnancy
Status: Enrolling
Updated: 11/23/2015
Strawberry Health Center
mi
from
Pasadena, TX
Click here to add this to my saved trials
Does Concomitant Use of Combined Oral Hormonal Steroids Stop Bleeding in Women Using Etonogestrel Implants (Implanon/Nexplanon®)?: A Randomized Controlled Study
Does Concomitant Use of Combined Oral Hormonal Steroids Stop Bleeding in Women Using Etonogestrel Implants (Implanon/Nexplanon®)?: A Randomized Controlled Study
Status: Enrolling
Updated:  11/24/2015
University of Colorado
mi
from
Aurora, CO
Does Concomitant Use of Combined Oral Hormonal Steroids Stop Bleeding in Women Using Etonogestrel Implants (Implanon/Nexplanon®)?: A Randomized Controlled Study
Does Concomitant Use of Combined Oral Hormonal Steroids Stop Bleeding in Women Using Etonogestrel Implants (Implanon/Nexplanon®)?: A Randomized Controlled Study
Status: Enrolling
Updated: 11/24/2015
University of Colorado
mi
from
Aurora, CO
Click here to add this to my saved trials
Understanding Women's Contraceptive Expectations at the Time of a First Trimester Surgical Abortion
Understanding Women's Contraceptive Expectations at the Time of a First Trimester Surgical Abortion
Status: Enrolling
Updated:  12/2/2015
University of California-Davis
mi
from
Sacramento, CA
Understanding Women's Contraceptive Expectations at the Time of a First Trimester Surgical Abortion
Understanding Women's Contraceptive Expectations at the Time of a First Trimester Surgical Abortion
Status: Enrolling
Updated: 12/2/2015
University of California-Davis
mi
from
Sacramento, CA
Click here to add this to my saved trials
Essure (Model ESS310) Placement Rate Study
A Multi-Center, United States Clinical Study to Evaluate Placement Success of the ESS310 Essure® System
Status: Enrolling
Updated:  12/14/2015
Clinical Research Facility
mi
from
Glendale, AZ
Essure (Model ESS310) Placement Rate Study
A Multi-Center, United States Clinical Study to Evaluate Placement Success of the ESS310 Essure® System
Status: Enrolling
Updated: 12/14/2015
Clinical Research Facility
mi
from
Glendale, AZ
Click here to add this to my saved trials
Essure (Model ESS310) Placement Rate Study
A Multi-Center, United States Clinical Study to Evaluate Placement Success of the ESS310 Essure® System
Status: Enrolling
Updated:  12/14/2015
Clinical Research Facility
mi
from
Phoenix, AZ
Essure (Model ESS310) Placement Rate Study
A Multi-Center, United States Clinical Study to Evaluate Placement Success of the ESS310 Essure® System
Status: Enrolling
Updated: 12/14/2015
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Essure (Model ESS310) Placement Rate Study
A Multi-Center, United States Clinical Study to Evaluate Placement Success of the ESS310 Essure® System
Status: Enrolling
Updated:  12/14/2015
Clinical Research Facility
mi
from
Colorado Springs, CO
Essure (Model ESS310) Placement Rate Study
A Multi-Center, United States Clinical Study to Evaluate Placement Success of the ESS310 Essure® System
Status: Enrolling
Updated: 12/14/2015
Clinical Research Facility
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Essure (Model ESS310) Placement Rate Study
A Multi-Center, United States Clinical Study to Evaluate Placement Success of the ESS310 Essure® System
Status: Enrolling
Updated:  12/14/2015
Clinical Research Facility
mi
from
Augusta, GA
Essure (Model ESS310) Placement Rate Study
A Multi-Center, United States Clinical Study to Evaluate Placement Success of the ESS310 Essure® System
Status: Enrolling
Updated: 12/14/2015
Clinical Research Facility
mi
from
Augusta, GA
Click here to add this to my saved trials
Essure (Model ESS310) Placement Rate Study
A Multi-Center, United States Clinical Study to Evaluate Placement Success of the ESS310 Essure® System
Status: Enrolling
Updated:  12/14/2015
Clinical Research Facility
mi
from
Fort Wayne, IN
Essure (Model ESS310) Placement Rate Study
A Multi-Center, United States Clinical Study to Evaluate Placement Success of the ESS310 Essure® System
Status: Enrolling
Updated: 12/14/2015
Clinical Research Facility
mi
from
Fort Wayne, IN
Click here to add this to my saved trials